Ubiquitin-Related Modifier 1 (URM-1) Modulates Cx43 in Breast Cancer Cell Lines
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24032958 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Layal El-Hajjar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut P.O. Box 11-0236, Lebanon. Hauptthemen laut MEDLINE: Breast Neoplasms, Connexin 43. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Practice Plan, University Research Board at the Faculty of Medicine at the American University of Beirut, Lebanese National Council for Scientific Research.
Abstract (Originalsprache)
Gap-junction-forming connexins are exquisitely regulated by post-translational modifications (PTMs). In particular, the PTM of connexin 43 (Cx43), a tumor suppressor protein, regulates its turnover and activity. Here, we investigated the interaction of Cx43 with the ubiquitin-related modifier 1 (URM-1) protein and its impact on tumor progression in two breast cancer cell lines, highly metastatic triple-negative MDA-MB-231 and luminal breast cancer MCF-7 cell lines. To evaluate the subsequent modulation of Cx43 levels, URM-1 was downregulated in these cells. The transcriptional levels of epithelial-to-mesenchymal transition (EMT) markers and the metastatic phenotype were assessed. We demonstrated that Cx43 co-localizes and interacts with URM-1, and URMylated Cx43 was accentuated upon cellular stress. The significant upregulation of small ubiquitin-like modifier-1 (SUMO-1) was also observed. In cells with downregulated URM-1, Cx43 expression significantly decreased, and SUMOylation by SUMO-1 was affected. The concomitant expression of EMT markers increased, leading to increased proliferation, migration, and invasion potential. Inversely, the upregulation of URM-1 increased Cx43 expression and reversed EMT-induced processes, underpinning a role for this PTM in the observed phenotypes. This study proposes that the URMylation of Cx43 in breast cancer cells regulates its tumor suppression properties and contributes to breast cancer cell malignancy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut P.O. Box 11-0236, Lebanon.
- Department of Biology, Faculty of Sciences, Lebanese University, Beirut P.O. Box 90656, Lebanon.
- Department of Public Health, Faculty of Health Sciences, University of Balamand, Beirut P.O. Box 100, Lebanon.
- Biomedical Research Center, Qatar University Doha, Doha P.O. Box 2713, Qatar.
- Department of Experimental Pathology, Immunology and Microbiology, Faculty of Medicine, American University of Beirut, Beirut P.O. Box 11-0236, Lebanon.
ORCID-Profile: Abdullah Shaito, Hiba El Hajj
Förderung
- Medical Practice Plan
- University Research Board at the Faculty of Medicine at the American University of Beirut
- Lebanese National Council for Scientific Research
Zitieren
APA
El-Hajjar, L., Saliba, J., Karam, M., Shaito, A., El Hajj, H., & El-Sabban, M. (2023). Ubiquitin-Related Modifier 1 (URM-1) Modulates Cx43 in Breast Cancer Cell Lines. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24032958
Vancouver
El-Hajjar L, Saliba J, Karam M, Shaito A, El Hajj H, El-Sabban M. Ubiquitin-Related Modifier 1 (URM-1) Modulates Cx43 in Breast Cancer Cell Lines. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24032958
BibTeX
@article{ElHajjar2023,
author = {El-Hajjar, Layal and Saliba, Jessica and Karam, Mario and Shaito, Abdullah and El Hajj, Hiba and El-Sabban, Marwan},
title = {Ubiquitin-Related Modifier 1 (URM-1) Modulates Cx43 in Breast Cancer Cell Lines},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24032958}
}
EUVIMED